ストックスクリーナーアプリを入手
0.9712
1.17%
0.0112
アフターアワーズ：
.97
-0.0012
-0.12%
前日終値:
$0.96
開ける：
$0.9787
24時間の取引高:
13,761
Relative Volume:
0.13
時価総額：
$24.98M
収益：
$9.06M
当期純損益:
$-50.39M
株価収益率:
-0.5058
EPS:
-1.92
ネットキャッシュフロー:
$5.89M
1週間 パフォーマンス:
+0.85%
1か月 パフォーマンス:
-1.90%
6か月 パフォーマンス:
-54.34%
1年 パフォーマンス:
-43.86%
1日の値動き範囲:
$0.95
$0.98
1週間の範囲:
$0.92
$0.989
52週間の値動き範囲:
$0.8807
$6.47
Lava Therapeutics Nv Stock (LVTX) Company Profile
LVTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
0.9712 | 24.98M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-19 | 開始されました | JP Morgan | Overweight |
| 2021-04-19 | 開始されました | Jefferies | Buy |
| 2021-04-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Lava Therapeutics Nv (LVTX) 最新ニュース
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com
Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria
Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India
JMP Securities Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
LAVA Therapeutics stock hits 52-week low at $1.35 - Investing.com
Lava Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - Investing.com Nigeria
LAVA Reports Third Quarter 2024 Financial Results and - GlobeNewswire
LAVA Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - The Manila Times
LAVA Therapeutics Pivots Strategy, Advances Cancer Drug Pipeline with Pfizer and J&J Partnerships - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 5.6% – Time to Sell? - Defense World
Some Major Key Players In The RNA Editing Market: - InsightAce Analytic
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
Lava Therapeutics shares hold target with Buy rating - Investing.com India
LAVA Therapeutics Shareholders Approve Key Resolutions - TipRanks
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com Australia
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive - Simply Wall St
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint - Yahoo Finance
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by - GlobeNewswire
Lava Therapeutics Nv (LVTX) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):